Healthcare Industry News: Vertex Pharmaceuticals
News Release - July 15, 2016
Bach Pharma Appoints Kelly Blackburn as Chief Executive OfficerNORTH ANDOVER, Mass., July 15, 2016 -- (Healthcare Sales & Marketing Network) -- Bach Pharma Inc., today announced the appointment of Kelly Blackburn as Chief Executive Officer and as a member of the Bach Pharma Board of Directors. Ms. Blackburn will lead the company into the next stage of development bringing the company's lead candidate, GVT, into the clinic.
Bach Pharma also announced that Mark O. Henry will serve as Chief Financial Officer, transitioning from his role as CEO. Mr. Henry expressed his enthusiasm regarding the addition of Ms Blackburn to the team: "Kelly is an accomplished executive in the healthcare industry who brings deep experience in running pharmaceutical operations to this role. We are thrilled to have her on board."
Ms. Blackburn was previously Vice President of Clinical Affairs at aTyr Pharma in San Diego, CA where as a member of the Executive Leadership Team, she was responsible for the oversight of clinical and regulatory plans for all programs. Ms. Blackburn has worked in several other pharmaceutical companies including Vertex Pharmaceuticals where she led the operations for their portfolio. Her successes include drug approvals for transformative therapies in Cystic Fibrosis, Hepatitis C and Multiple Myeloma.
About Bach Pharma
Bach Phama Inc, a privately held pharmaceutical company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life threatening diseases. Bach is targeting the development of therapies for life threatening oxidative stress-related diseases with the goal to dramatically improve patients' lives and reduce global health care costs.
Source: Bach Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.